Other
Federal
Vertex Pharmaceuticals Federal remained flat by 0.0% to -$131.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 20.1%, from -$109.68M to -$131.75M. Over 2 years (FY 2023 to FY 2025), Federal shows relatively stable performance with a -3.8% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Indicates timing differences between accounting profit and taxable income.
Detailed definition
The change in deferred federal tax liabilities or assets resulting from temporary differences between the financial repo...
Peer comparison
Standard tax disclosure for all corporations.
Metric ID:
other_deferred_federal_income_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$569.90M | -$438.70M | -$527.00M |
| YoY Change | — | +23.0% | -20.1% |
Range-$569.90M – -$438.70M
CAGR-3.8%
Avg YoY Growth+1.4%
Median YoY Growth+1.4%
Federal at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's federal?
- Vertex Pharmaceuticals (VRTX) reported federal of -$131.75M in Q4 2025.
- How has Vertex Pharmaceuticals's federal changed year-over-year?
- Vertex Pharmaceuticals's federal decreased by 20.1% year-over-year, from -$109.68M to -$131.75M.
- What is the long-term trend for Vertex Pharmaceuticals's federal?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's federal has grown at a -3.8% compound annual growth rate (CAGR), from -$569.90M to -$527.00M.
- What does federal mean?
- Federal tax expense or benefit that will be realized in future periods.